Results 241 to 250 of about 106,400 (334)

Can ISO/IEC 17025 serve as a tool to prevent scientific fraud in chemical research laboratories?

open access: yesThe Canadian Journal of Chemical Engineering, EarlyView.
Abstract Scientific fraud has been documented across multiple disciplines, and chemistry is no exception. Recent studies indicate that contamination of materials, methodological errors, and unreliable data, results, or analyses account for over 25% of retracted publications.
Flor Monica Gutierrez‐Alcantara
wiley   +1 more source

Characteristics of retracted biomedical research papers from Latin American institutions. [PDF]

open access: yesRev Saude Publica
Ramos-Castaneda JA   +5 more
europepmc   +1 more source

Overall effectiveness factor of an assemblage of catalyst pellets with different sizes or properties

open access: yesThe Canadian Journal of Chemical Engineering, EarlyView.
Abstract Catalyst assemblages comprising pellets with distributed sizes or physicochemical properties are ubiquitous in industrial processes; yet accurately predicting their overall effectiveness factors remains a challenge due to complex diffusion–reaction interactions.
Bahador Abolpour, Hong Yong Sohn
wiley   +1 more source

Partial identification with categorical data and nonignorable missing outcomes

open access: yesCanadian Journal of Statistics, EarlyView.
Abstract Nonignorable missing outcomes are common in real‐world datasets and often require strong parametric assumptions to achieve identification. These assumptions can be implausible or untestable, and so we may wish to forgo them in favour of partially identified models that narrow the set of a priori possible values to an identification region.
Daniel Daly‐Grafstein, Paul Gustafson
wiley   +1 more source

In Vivo Cytoskeletal AMPA Receptor Transport Imaging in C. elegans

open access: yesCytoskeleton, EarlyView.
ABSTRACT Long‐distance intracellular transport of ionotropic glutamate receptors (iGluRs) is essential for proper excitatory synaptic function underlying learning and memory. Many neuropsychiatric and neurodegenerative conditions have abnormal iGluR transport and trafficking, leading to an intense interest in the mechanisms and factors regulating these
Michaelis A. K., Hoerndli F. J.
wiley   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5‐HT3 Receptor Antagonists: 2026 Update

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy